News About: Pharm. Industry
New homegrown antimalarial drug to be approved in first half
The Korea Food and Drug Administration is likely to approve Pyramax, an investigational antimalarial medicine developed by Shinpoong Pharmaceutical Co, possibly in the first half of this year.
Pyramax is a fixed-do...
Boehringer Ingelheim's Pradaxa to garner bigger sales in Korea
Pradaxa (dabigatran etexilate), which was approved by the Korea Food and Drug Administration on February 18, will hit the domestic blood thinning products market, according to market experts.
Pradaxa is an anticoag...
Zydena takes on Viagra, Cialis
Dong-A Pharmaceutical, Korea’s No. 1 drug maker, is enjoying brisk sales of its new anti-impotence drug, Zydena.
Sales of Dong-A’s erectile dysfunction medicine reached over 80 billion won (equivalent to 10 millio...
Green Cross emerges as No. 2 drugmaker
The local pharmaceutical industry is undergoing a major change in the reshuffle of the leader board of drug manufacturers.
Dong-A Pharmaceutical kept its number 1 ranking in terms of revenue for over four decades, ...
Green Cross to co-promote Ipsen’s Diphereline
Green Cross Corp. said Thursday that it has signed an agreement with Ipsen Korea to co-market Diphereline (triptorelin) in Korea.
Diphereline is triptorelin, a decapeptide analogue of GnRH (Gonadotrophin Releasing ...
Lilly Korea changes package of Cialis 20 mg pills
Cialis is a popular impotence drug and has achieved remarkable success, but now fake Cialis sale online is prompting Lilly Korea to change the package of Cialis 20 mg pills as part of efforts to distinguish Cialis bet...
KPMA to set up biotech medicine department
The Korea Pharmaceutical Manufacturers Association has a plan to establish a new biotech medicine department as part of its efforts to help globalize the domestic biotech medicines industry.
The department will hav...
Medison seeking to consolidate global position
New CEO Bang Sang-won of Medison, a Seoul-based ultrasonic diagnostic equipment manufacturer, has recently unveiled his plan to grow the company into the third-largest player in the world diagnostic ultrasound system ...
BMS’s Baraclude increase market share
The US based Bristol Myers Squibb’s Baraclude (entecavir) for treatment of hepatitis B accounted for about 50 percent of the sector’s domestic sales last year, an industry report showed yesterday.
Just within to tw...
Cash reward system will hurt pharmaceutical sector
Korea’s pharmaceutical sector could lose up to 1.4 trillion won due to the current drug pricing reform, which has provided cash rewards to doctors and pharmacists who refuse to take rebates and instead purchase medici...
